Quick Answer
Cartesian Therapeutics, Inc. reported Total Assets of $296.41 million for the year ending 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -31.9% in Total Assets from 2024 to 2025.
- This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: $91.32 million | Q3 2016: $85.78 million | Q1 2017: $73.86 million | Q2 2017: $117.03 million | Q3 2017: $109.72 million | Q1 2018: $89.94 million | Q2 2018: $73.44 million | Q3 2018: $60.32 million | Q1 2019: $62.48 million | Q2 2019: $46.95 million | Q3 2019: $39.54 million | Q1 2020: $88.80 million | Q2 2020: $75.21 million | Q3 2020: $181.00 million | Q1 2021: $176.75 million | Q2 2021: $180.52 million | Q3 2021: $167.16 million | Q1 2022: $145.70 million | Q2 2022: $188.07 million | Q3 2022: $178.27 million | Q1 2023: $155.69 million | Q2 2023: $139.51 million | Q3 2023: $106.03 million | Q1 2024: $325.21 million | Q2 2024: $347.74 million | Q3 2024: $455.32 million | Q1 2025: $409.13 million | Q2 2025: $388.89 million | Q3 2025: $372.68 million.
- Over the full 11 years of available data (2015 to 2025), Cartesian Therapeutics, Inc.'s Total Assets has grown by 592.2%.
- Historical annual values: Fiscal year 2025: $296.41 million | Fiscal year 2024: $435.02 million | Fiscal year 2023: $305.05 million | Fiscal year 2022: $165.89 million | Fiscal year 2021: $159.88 million | Fiscal year 2020: $165.44 million | Fiscal year 2019: $99.57 million | Fiscal year 2018: $44.48 million | Fiscal year 2017: $101.10 million | Fiscal year 2016: $89.30 million | Fiscal year 2015: $42.82 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: